Design Therapeutics, Inc. (DSGN)

Market Cap	223.10M
Revenue (ttm)	n/a
Net Income (ttm)	-56.20M
Shares Out	56.77M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,804
Open	3.980
Previous Close	4.000
Day's Range	3.905 - 3.980
52-Week Range	2.600 - 7.770
Beta	1.57
Analysts	Hold
Price Target	4.00 (+1.78%)
Earnings Date	Aug 4, 2025

About DSGN

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ sys...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: DSGN
• Website: https://www.designtx.com

Analyst Summary

According to one analyst, the rating for DSGN stock is "Hold" and the 12-month stock price target is $4.0.

Price Target

$4.0

(1.78% upside)

Analyst Consensus: Hold